← Eichor
Study identifier: NCT06512519 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Second Haplo-transplantation for Graft Failure

Condition: Graft Failure · Stem Cell Transplant Complications  ·  Sponsor: Peking University People's Hospital

PhaseNA
Planned participants34
Who can joinAll sexes, 14 Years to no upper limit
Healthy volunteersNo

About this study

Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. There are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). However, the study was performed in single-center and with very small sample size. Therefore, it should be further validated via multicenter study. In this multi-center study, we aim to further evaluate the safety and efficacy of this protocol.

This description comes directly from the study's public registry record.

Talk to the study team

Yu-qian Sun, M.D.  ·  +86-10-88324577  ·  sunyuqian83@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University People's HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06512519